The only pharmaceutical company in Australia which supplies a critical ADHD drug will not be allowed to ramp up production even though there's a serious global shortage. US drug officials who control the key ingredient behind Vyvanse have refused to raise manufacturing limits despite pleas from Australian psychiatrists who say patients are suffering.
